Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Human bone marrow-derived, pooled, allogeneic mesenchymal stromal cells manufactured from multiple donors at different times show comparable biological functions in vitro, and in vivo to repair limb ischemia

Fig. 3

Quantification of angiogenic growth factors. a VEGF (A), b SDF-1α, c IL-8, and d TGFβ1 levels in the CM collected at the 72 h time point from Stempeucel®-1 and Stempeucel®-1A batches. Significant variation in the levels was observed between the two Stempeucel® versions, VEGF—**P = 0.001; SDF-1α—*P = 0.01; IL-8—***P = 0.0006; TGFβ1—**P = 0.003. e The CMs derived from both Stempeucel®-1 and Stempeucel®-1A promoted HUVEC migration equally. Addition of anti-VEGF mAb in the CMs significantly inhibited HUVEC migration (Stempeucel®-1 = 61.6%; Stempeucel®-1A = 61.6%). f Equivalent HUVEC proliferation was observed with both Stempeucel®-derived CM. Significant inhibition in HUVEC proliferation was observed upon neutralizing VEGF in the CMs (Stempeucel®-1 = 97.9, Stempeucel®-1A = 100%). g No significant difference in the HUVEC tube formation efficiency was observed between the CMs derived from Stempeucel®-1 and Stempeucel®-1A and similar inhibition (Stempeucel®-1 = 69.6%, Stempeucel®-1A = 65.1%) was observed between the two CMs in the presence of anti-VEGF mAb; a, b Similar HUVEC tube forming efficiency was observed with the CMs from both Stempeucel®-1 and Stempeucel®-1A. EGM—endothelial growth medium control; KO + 10%FBS – DMEM-KO basal medium plus 10% FBS control; SFM: serum-free DMEM-KO medium. Graphs represent mean ± SEM values

Back to article page